Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kola Adegoke has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 17 November 2026
    • Published by MDPI AG in Preprints.org
      • https://doi.org/10.20944/preprints202611.1704.v1
    Open Access

    Before Peer Review: Partnership Networks and Access to Canadian Health Research Funding

    by Kola Adegoke

    Funding competitions that require an implementing partner make access to research partly dependent on relationships established before peer review. Using a Canadian Institutes of Health Research youth mental health competition, this commentary examines that barrier for newcomers to partnership networks, with particular attention to Black researchers and Black-led organizations. Canada has relevant planning mechanisms, including support from the Institute of Neurosciences, Mental Health and Addiction. The proposed adaptation is to align exploratory funding with competition deadlines, allow initial expressions of interest before formal partnership commitments, and fund community and youth participation in planning. Funders should monitor progression from registration to submission and seek brief, voluntary feedback on partnership formation. Such monitoring should protect privacy, acknowledge incomplete coverage and nonresponse, and respect organizations’ freedom to decline collaboration.

  • Open Access

    Beyond eGFR: Mechanistic Kidney Models for High Renal Clearance and Prediction of Drug Disposition in Renal Impairment

    by Matthew Chibunna Igwe, Ogbonna Alphonsus Ogbuabor, Esther Ugo Alum, Peter Uchogu Ahmadu, Kola Adegoke

    Background. Renal drug elimination is incompletely captured by estimated glomerular filtration rate (eGFR) alone. It reflects filtration, transporter-mediated secretion, passive/active reabsorption, renal blood flow, and sometimes metabolism, so proportional GFR scaling may be inadequate for high-clearance drugs, transporter substrates, and advanced chronic kidney disease (CKD).Objective. This review evaluates the basis, structure, verification, applications, and limitations of mechanistic kidney models for renal drug disposition, emphasizing tubular secretion, reabsorption, CKD adaptation, transporter biomarkers, uremic inhibition, and extracorporeal clearance.Evidence synthesis. Renal clearance cannot always be represented by a single GFR-dependent factor. Adaptive tubular flow and water handling affect passive reabsorption in advanced CKD: absolute fold error for reabsorption-prone compounds was 1.05–1.73 with an adaptive model versus 2.61–7.35 with a non-adaptive, proportionally scaled model at CKD stages 4–5 [1]. Transporter-mediated secretion can decline independently of GFR; uremic solutes inhibiting renal organic anion transporters shifted a tenofovir PBPK model from failing to passing a pre-defined 2-fold acceptance criterion [2]. Endogenous biomarkers offer emerging, independent strategies for estimating renal transporter function: pyridoxic acid has been developed as a population-informed biomarker of OAT1/3 activity for predicting transporter-mediated drug-drug interactions [3], and a separate biomarker-informed model combining estimated secretory clearance and renal blood flow with GFR produced only modest improvements in mean absolute prediction error relative to a regression-based comparator [4] a more cautious result than the pyridoxic acid work alone might suggest, and the two lines of evidence are kept distinct in this review. Simple GFR-based methods can match or exceed PBPK models in some direct comparisons (95.0% vs. 93.1% of observations within a 2-fold error band, 33 drugs), so complexity should track elimination mechanism [5].Conclusions. Mechanistic kidney models distinguish filtration, secretion, and reabsorption and incorporate disease-related physiological change, with greatest value for high renal extraction, substantial transporter secretion, nonlinear handling, or marked CKD uncertainty. Progress requires better transporter, biomarker, and extracorporeal-clearance data and standardized verification criteria; mechanistic modelling should complement, not replace, GFR-based approaches.

  • Open Access

    Did Maryland’s All-Payer Global Budget Revenue Model Change Hospital Margins and Revenue per Discharge? A Difference-in-Differences Analysis of Maryland and Massachusetts, 2010–2023

    by Kola Adegoke

    Background: Maryland implemented an all-payer hospital global budget revenue (GBR) model in 2014 to decouple hospital revenue from volume and improve revenue predictability. This study evaluated whether Maryland’s 2014 GBR implementation was associated with differential changes in hospital total margins, inpatient revenue per discharge, and COVID-period margin volatility relative to Massachusetts. Methods: A matched hospital-year panel for Maryland and Massachusetts spanning 2010–2023 (2,261 matched observations) was constructed by merging Medicare cost report-based financial measures with provider characteristics using CMS certification identifiers. Two-way fixed-effects difference-in-differences models with hospital and year fixed effects and hospital-clustered standard errors estimated post-2014 changes in outcomes in Maryland relative to Massachusetts. Identification was assessed using an event-study specification and a placebo test (fake treatment in 2012, restricted to the pre-period). Financial stability under pandemic shock was evaluated using a COVID-period differential effect on margin volatility, defined as the absolute year-over-year change in total margin. An additional restricted sensitivity analysis for 2010–2019 adjusted for available case-mix and payer-mix covariates. Results: GBR implementation was not associated with a statistically detectable change in total margins (β = 0.021, p = 0.232). In contrast, GBR was associated with higher log inpatient revenue per discharge in Maryland relative to Massachusetts after 2014 (β = 0.287, p = 0.003), consistent with an approximate 33% increase in revenue per discharge (exp[0.287]−1). However, in the restricted 2010–2019 sensitivity analysis adjusting for available case-mix and payer-mix covariates, this association was attenuated and no longer statistically significant (β = 0.030, p = 0.513). Margin volatility during COVID-19 did not differ significantly between states (β = −0.018, p = 0.161). The placebo test showed no spurious effect in the pre-period (β = −0.008, p = 0.801), supporting the validity of the design. Conclusions: Maryland’s all-payer global budgets were associated with higher revenue per discharge in the primary model, but with no detectable change in total margins or in differential margin volatility during COVID-19. The revenue-per-discharge finding was sensitive to adjustment for available case-mix and payer-mix covariates in a restricted sensitivity analysis, supporting a cautious interpretation. These findings are consistent with GBR altering revenue intensity without clear evidence of improved profitability or shock-absorbing effects over 2010–2023.

  • Open Access

    Most-Favored-Nation Benchmarking Versus Value-Based Contracting: Institutional Fit of Pharmaceutical Pricing Tools in the United States, Canada, and the United Kingdom

    by Kola Adegoke, Olajide Alfred Durojaye, Abimbola Adegoke, Adeyinka Adegoke

    Background: Soaring drug prices pose a significant obstacle to affordable and equitable access to medicines in high-income healthcare systems. This study compares two leading reform tool families, Most Favored Nation (MFN)/international reference pricing (IRP) and value-based contracting (VBC), across the United States, Canada, and the United Kingdom, with attention to cost containment, value-linked incentive design, equity of access, and implementation feasibility. U.S. policy developments (CMS Innovation Center’s GENEROUS, GLOBE, and GUARD models) extend international benchmark-based design options beyond the 2020 MFN rule. Methods: Guided by institutional and governance theories, we conducted a structured comparative policy analysis using a four-dimensional trade-off matrix. Cases from the United States, Canada, and the United Kingdom were selected using a most-different-systems design. Documents from 2007 to 2025 were coded for cost containment, value-linked incentive design, equity, and implementation feasibility. To reduce subjectivity, scores were assigned using prespecified rubric anchors, conservative scoring rules for borderline cases, and a sensitivity check of adjacent-score judgments. Design-stage U.S. benchmark-based model materials assessed on March 5, 2026, were incorporated descriptively and not considered as outcome evidence. Results: The United Kingdom model, centered on the National Institute for Health and Care Excellence (UK NICE) and the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), was most consistently aligned across all four dimensions (design-feature alignment). Canada’s Patented Medicine Prices Review Board (PMPRB) supports affordability and baseline access, with implementation variation across provinces and more limited adoption of outcomes-based contracting. U.S. MFN/IRP initiatives and VBC pilots show lower alignment on equity and feasibility in a multi-payer environment characterized by contested authority and variable data/contracting capacity. Emerging CMS Innovation Center proposals (GENEROUS, GLOBE, GUARD) indicate continued federal interest in benchmark-based designs, but empirical impacts remain to be evaluated. Conclusions: MFN/IRP anchoring and VBC are implementation-intensive tools whose performance depends on institutional fit. A hybrid approach, using international benchmarks as inputs for negotiations and expanding value-linked agreements where measurement and governance prerequisites are met, may offer a more feasible U.S. pathway. This study provides a repeatable framework for assessing drug pricing reforms and illustrates how institutional alignment conditions the implementability of tools. Design-feature scores reflect policy design and governance capacity, not realized outcomes.

  • Open Access

    From crisis to recovery: Exploring the demand surge for mental health services in Alberta, Canada—A document-based policy analysis with an illustrative supply–demand simulation (2023–2024)

    by Kola Adegoke, Abimbola Adegoke, Deborah Dawodu, Ayoola Bayowa, Akorede Adekoya, Temitope Kayode, Mallika Singh, Olajide Alfred Durojaye, Abiodun Isola Aluko, Adeyinka Adegoke

    COVID-19 coincided with increased mental health needs in Alberta, Canada, intensifying pre-existing access gaps and service strain. Alberta responded with publicly funded interventions spanning digital care, youth-focused services, and recovery-oriented programs. To evaluate Alberta’s system-level response to pandemic-related increases in mental health help-seeking/service uptake using a health economics and policy lens. We extracted empirically reported program delivery outputs from the 2023–2024 Alberta Mental Health and Addiction Annual Report. We used a simulation calibrated to reported trends to examine directional changes in help-seeking (demand), service capacity (supply), and the modeled equilibrium quantity under a zero-copayment design. Empirically reported outputs indicate that delivery met or exceeded planned/funded milestones for CASA Mental Health, VODP, and tele-mental health, while recovery communities reflected phased implementation. In the illustrative simulation, the demand-implied volume increases from 60 to 87 services/month, but delivered volume is capacity-constrained at 78 services/month (implying ~9 services/month unmet demand), while a unit-cost proxy is held constant for visualization (not an observed market price or patient copayment). Alberta’s response illustrates how coordinated, publicly funded capacity expansion and access-oriented policies can support service delivery during system shocks; the model also highlights that if capacity growth lags demand growth, unmet need may persist even under zero copayment.

  • Open Access

    Medicaid Expansion and Frequent Mental Distress Among U.S. Adults: Staggered DiD Using BRFSS, 2011 to 2024

    by Abimbola Adegoke, Kola Adegoke, Olajide Alfred Durojaye, Deborah Dawodu, Abiodun Isola Aluko, Akorede Adekoya, Kenneth A. Knapp

    The Affordable Care Act (ACA) allowed states to expand Medicaid eligibility, potentially improving access to care and reducing psychological distress among lower-income adults. However, evidence on population-level mental health effects remains mixed, and conventional two-way fixed-effects difference-in-differences (DiD) estimates can be biased under staggered adoption. This study estimates the effect of Medicaid expansion on frequent mental distress (FMD) among non-elderly adults, with emphasis on lower-income adults. We used Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 to 2024 and restricted the sample to adults aged 18 to 64 years. FMD was defined as ≥14 days of poor mental health in the past 30 days. Medicaid expansion was assigned by state implementation year. For transparent weighting and computational feasibility, we collapsed microdata to state-year prevalence using BRFSS survey weights and applied prespecified minimum cell-size and effective-sample screens (lower-income panel: unweighted N ≥ 150 and Kish n_eff ≥ 50; pooled and higher-income panels: n_eff ≥ 200). We estimated group-time average treatment effects using the Callaway–Sant’Anna staggered DiD framework (csdid), clustered standard errors at the state level, and used pair-balanced observations when panels were unbalanced. Income strata were defined using BRFSS household income categories (lower-income: inc_cat = 1; higher-income: inc_cat ∈ {7,8}) and are interpreted as economic-status proxies rather than Medicaid eligibility. In the lower-income state-year panel (353 state-years), Medicaid expansion was not associated with a statistically significant change in FMD (ATT −0.0125; 95% CI −0.0521 to 0.0271; P = .54). Estimates in the higher-income (656 state-years) and pooled (709 state-years) panels were similarly small and not statistically significant. Event-time estimates indicated modest heterogeneity at selected leads/lags without a consistent post-expansion pattern. Medicaid expansion was not associated with significant reductions in population-level frequent mental distress during 2011 to 2024. Any mental health effects appear modest and heterogeneous across cohorts and follow-up periods, suggesting that insurance expansion alone may be insufficient to shift population psychological distress without complementary behavioral health capacity and upstream social supports.


  • Open Access

    Did Maryland All-Payer Global Budgets Change Hospital Margins and Revenue per Discharge? A Comparative Interrupted Panel Analysis, 2010–2023 (Maryland vs. Massachusetts)

    by Kola Adegoke

    Background: Maryland implemented an all-payer hospital global budget revenue (GBR) model in 2014 to decouple hospital revenue from volume and promote financial stability. Whether GBR altered hospital financial performance, particularly margins and inpatient revenue intensity, relative to comparable fee-for-service settings, remains contested. Methods: A matched hospital–year panel for Maryland and Massachusetts spanning 2010–2023 (2,261 matched observations) was constructed by merging Medicare cost report–based financial measures with provider characteristics using CMS certification identifiers. Two-way fixed-effects difference-in-differences models with hospital and year fixed effects and hospital-clustered standard errors estimated post-2014 changes in outcomes in Maryland relative to Massachusetts. Identification was assessed using a dynamic event-study specification and a placebo test (fake treatment in 2012, restricted to the pre-period). Financial stability under pandemic shock was evaluated using a COVID-period differential effect on margin volatility, defined as the absolute year-over-year change in total margin. Results: GBR implementation was not associated with a statistically detectable change in total margins (MD×post2014 β=0.021, p=0.232). In contrast, GBR was associated with higher inpatient revenue per discharge (log) in Maryland relative to Massachusetts after 2014 (MD×post2014 β=0.287, p=0.003), consistent with an approximate 33% increase in revenue per discharge (exp [0.287]−1). Margin volatility during COVID-19 did not differ significantly between states (MD×COVID β=−0.018, p=0.161). The placebo test showed no spurious “effect” in the pre-period (MD×placebo β=−0.008, p=0.801), supporting design validity. Conclusions: Maryland’s all-payer global budgets were associated with higher revenue per discharge but no detectable change in operating margins or differential margin volatility during COVID-19. These findings are consistent with GBR altering revenue intensity without clear evidence of improved profitability or shock-absorbing effects over 2010–2023.

  • Open Access

    Health Information Technology Capital Intensity and Hospital Financial Performance: Evidence from U.S. Hospitals, 2018–2023

    by Kola Adegoke, Eunice Bisola Akano, Anuoluwapo Deborah Bayowa, Abimbola Adegoke, Akorede Adekoya, Soe Soe Htun, Alexis Geist, Jesus Vasquez, Meghan Appel, Ferdousi Zaman

    Background: U.S. hospitals continue to invest in digital infrastructure, yet evidence on how health information technology (HIT) capital investment relates to financial performance, particularly after COVID-19, remains mixed.Objective: To estimate associations between HIT capital intensity and hospital profitability from 2018 to 2023, assess nonlinearity, and test whether associations differed during the COVID-19 years. Methods: Using the RAND HCRIS hospital panel (3,480 hospital-year observations from HIT-reporting hospitals, 2018–2023), we defined HIT capital intensity as HIT-designated capital stock divided by total assets. Primary analyses estimated year-specific regressions with HIT-intensity quintiles and spline specifications for nonlinearity, adjusting for hospital size (log total assets) and teaching status. Pooled models incorporated year fixed effects and HIT-intensity interactions with a COVID indicator (2020–2021). Sensitivity analyses included alternative winsorization (5th/95th percentile), hospital-fixed effects, and placebo tests using non-HIT fixed-asset intensity.Results: Reporter rates ranged from 24.6% (2018; 545/2,212) to 19.4% (2023; 982/5,063). In year-specific quintile models, the highest HIT-intensity quintile (Q5) was associated with lower winsorized total margin versus Q1 in 2018 (β = −0.055; p = 0.008), 2019 (β = −0.042; p = 0.016), and 2023 (β = −0.034; p = 0.010), with weaker estimates in 2020–2022. In pooled interaction models, higher-intensity hospitals exhibited a lower margin gap outside COVID years (e.g., Q5: β = −0.041; p < 0.001) with partial attenuation during COVID (Q5×COVID: β = 0.032; p = 0.073). Hospital fixed-effects estimates for quintiles were not statistically significant (Q5: β = −0.015; p = 0.438). A pooled 5/95 winsorization robustness check remained negative for Q5 (β = −0.029; p < 0.001). Placebo analyses showed similar patterns for non-HIT fixed assets (Q5: β = −0.032; p = 0.006). Conclusions: Higher HIT capital intensity is associated with lower profitability at the upper end of the intensity distribution in some years, with suggestive attenuation during COVID-19. However, the fixed-effects and placebo results are consistent with time-invariant confounding or broader capital-intensity dynamics rather than HIT-specific causal effects. Policies targeting financially constrained hospitals may help sustain digital investment while protecting financial stability.

  • Open Access

    Financial Margin Dynamics After Hospital Chain-Joining: A Staggered DiD Event Study, 2014–2023

    by Kola Adegoke, Olajide Alfred Durojaye, Abimbola Adegoke, Deborah Dawodu, Adeyinka Adegoke, Anuoluwapo Deborah Bayowa, Eunice Bisola Akano

    Background: U.S. hospitals have increasingly affiliated with multi-hospital chains, raising questions about whether consolidation yields operational efficiencies or primarily reflects integration costs and market power. Evidence on the dynamic financial response to chain entry—especially in recent years—remains limited.Objective: To estimate dynamic association in hospital financial margins around sustained chain joining using a staggered-adoption-robust event-study design.Methods: We analyzed a RAND-processed HCRIS hospital panel (2014–2023). Dynamic effects were estimated using the Sun & Abraham interaction-weighted event-study estimator with hospital and year fixed effects and hospital-clustered standard errors. We implemented two baseline rules (“has2014” and “entry”) and examined total, operating, and cash-flow margins. To reduce ratio outliers, margins were cleaned using year-specific denominator screening and hard caps for extreme values (|margin|>500%), then winsorized within year (p1/p99) for main analyses. Depending on outcome and baseline rule, models used approximately 13,000–24,000 hospital-year observations, covering ~2,600–2,900 hospitals and roughly 600 sustained chain joins. Robustness checks included a balanced-panel restriction, a treated-only stacked specification, placebo assignment among never-treated hospitals, and ownership-stratified estimates.Results: Lead coefficients were generally small, but cash-flow margins exhibited a statistically detectable negative lead at t = −4 in both baseline rules (p≈0.03), while other leads were typically indistinguishable from zero. Post-entry effects were modest and imprecise across outcomes. Total margins showed near-zero contemporaneous changes at t=0 and small negative estimates in years 1–3 that attenuated by year 4. Operating and cash-flow margins displayed small post-entry declines around t=2 (≈1 percentage point in magnitude; p≈0.06–0.09). Robustness checks (balanced panel, stacked design, placebo) broadly supported a null or weak-transient pattern. Ownership stratification suggested modest longer-run improvements for nonprofit hospitals in later post years (e.g., t=4: +3.7 percentage points; p=0.045), while for-profit estimates were mixed and imprecise.Conclusions: Over 2014–2023, sustained chain joining was not associated with consistent, sustained improvements in hospital financial margins on average. Observed changes were small, often imprecise, and in some outcomes suggest modest short-run declines consistent with integration costs. Continued monitoring with longer post-entry windows and additional outcomes is warranted.

  • Open Access

    From Crisis to Recovery: Mental Health Service Demand in Alberta, Canada — A Policy Analysis with Illustrative Supply–Demand Modeling (2023–2024)

    by Kola Adegoke, Abimbola Adegoke, Deborah Dawodu, Ayoola Bayowa, Akorede Adekoya, Temitope Kayode, Mallika Singh, Olajide Alfred Durojaye, Abiodun Isola Aluko, Adeyinka Adegoke

    Background: COVID-19 coincided with increased mental health needs in Alberta, Canada, intensifying pre-existing access gaps and service strain. Alberta responded with publicly funded interventions spanning digital care, youth-focused services, and recovery-oriented programs. Objective: To evaluate Alberta’s system-level response to pandemic-related increases in mental health help-seeking/service uptake using a health economics and policy lens. Methods: We extracted empirically reported program delivery outputs from the 2023–2024 Alberta Mental Health and Addiction Annual Report. We used a simulation calibrated to reported trends to examine directional changes in help-seeking (demand), service capacity (supply), and the modeled equilibrium quantity under a zero-copayment design. Results: Empirically reported outputs indicate that delivery met or exceeded planned/funded milestones for CASA Mental Health, VODP, and tele-mental health, while recovery communities reflected phased implementation. In the illustrative simulation, the demand-implied volume increases from 60 to 87 services/month, but delivered volume is capacity-constrained at 78 services/month (implying ~9 services/month unmet demand), while a unit-cost proxy is held constant for visualization (not an observed market price or patient copayment).Conclusion: Alberta’s response illustrates how coordinated, publicly funded capacity expansion and access-oriented policies can support service delivery during system shocks; the model also highlights that if capacity growth lags demand growth, unmet need may persist even under zero copayment.